Journal article
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, Q Chen, N Dimopoulos, T Luke, R Murphy, AM Scott, E Maraskovsky, G McArthur, D MacGregor, S Sturrock, TY Tai, S Green, A Cuthbertson, D Maher, L Miloradovic Show all
Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2004
Abstract
NY-ESO-1 is a "cancer-testis" antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-controlled clinical trial evaluating the safety and immunogenicity of recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant. Forty-six evaluable patients with resected NY-ESO-1-positive tumors received three doses of vaccine intramuscularly at monthly intervals. The vaccine was well tolerated. We observed high-titer antibody responses, strong delayed-type hypersensitivity reactions, and circulating CD8+ and CD4+ T cells specific for a broad range of NY-ESO-1 epitopes, including known and previously unknown epitopes. In an u..
View full abstract